Decision making and uncertainty quantification for individualized treatments

TL;DR

This paper introduces a Bayesian approach using BART models to develop and evaluate individualized treatment rules, enabling personalized treatment decisions with uncertainty quantification and improved health outcomes.

Contribution

It proposes a novel method combining Bayesian Additive Regression Trees with treatment decision strategies, allowing for flexible, interpretable, and uncertainty-aware individualized treatment rules.

Findings

Method outperforms existing approaches in simulations.

Effectively quantifies uncertainty in treatment decisions.

Successfully applied to hematopoietic cell transplantation data.

Abstract

Individualized treatment rules (ITR) can improve health outcomes by recognizing that patients may respond differently to treatment and assigning therapy with the most desirable predicted outcome for each individual. Flexible and efficient prediction models are desired as a basis for such ITRs to handle potentially complex interactions between patient factors and treatment. Modern Bayesian semiparametric and nonparametric regression models provide an attractive avenue in this regard as these allow natural posterior uncertainty quantification of patient specific treatment decisions as well as the population wide value of the prediction-based ITR. In addition, via the use of such models, inference is also available for the value of the Optimal ITR. We propose such an approach and implement it using Bayesian Additive Regression Trees (BART) as this model has been shown to perform well in fitting nonparametric regression functions to continuous and binary responses, even with many covariates. It is also computationally efficient for use in practice. With BART we investigate a treatment strategy which utilizes individualized predictions of patient outcomes from BART models. Posterior distributions of patient outcomes under each treatment are used to assign the treatment that maximizes the expected posterior utility. We also describe how to approximate such a treatment policy with a clinically interpretable ITR, and quantify its expected outcome. The proposed method performs very well in extensive simulation studies in comparison with several existing methods. We illustrate the usage of the proposed method to identify an individualized choice of conditioning regimen for patients undergoing hematopoietic cell transplantation and quantify the value of this method of choice in relation to the Optimal ITR as well as non-individualized treatment strategies.